John: When I got diagnosed with AML ah nobody in my family had it.
John: I was told it was pretty rare and fast-moving.
Cherie: It was daunting, it was enriching.
Cherie: We learned a lot, and in many ways we became closer.
John: Going in there I knew I was on a clinical trial.
Cherie: We were just so blessed to be there at the right time at the right place and have a spot that they wanted an old man to try.
John: Being on a clinical trial was… well it saved me, really.
John: Being in the hospital you know you’re going to have time other than being interrupted every four hours for a lot of things and I decided I’m going to keep a log of what happens. You-you know you’re going to have time in between and so I did a lot of walking and they told me when I checked into that hospital that 11 times around the out- the per-perimeter was a mile. So I set goals, I’m gonna do my exercise.
John: There were a few days where I had trouble getting up and ah I did walk around but I didn’t record… I mentioned that I didn’t do any laps. What I call laps are when I was really moving… and ah I did get up and walk around very slowly and… those days I didn’t do much. But I had to try and do something.
John: My advice for somebody going through this is have the support, have a positive positive attitude, keep in shape, the best shape you can be.
John: Ah We - we look at it like it’s a new day every day.
VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
IMPORTANT SAFETY INFORMATION
AML=acute myeloid leukemia; AML-MRC=AML with myelodysplasia-related changes.